Quantitative RT-PCR analysis of the MOZ-CBP fusion transcript in therapy-related acute myeloid leukemia with t(8;16)(p11;p13)

Journal of Pediatric Hematology/Oncology

Volumn 34, Issue 5, 2012, Pages 402-405

  Fujiki, Atsushi ^a   Imamura, Toshihiko ^a   Furutani, Akiyo ^a   Hatano, Waka ^a   Asai, Daisuke ^a   Hirashima, Yoshifumi ^a   Miyachi, Mitsuru ^a   Tamura, Shinichi ^b   Tsuchiya, Kunihiko ^a   Iehara, Tomoko ^a   Ishida, Hiroyuki ^b   Yoshihara, Takao ^b   Hosoi, Hajime ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MATSUSHITA MEMORIAL HOSPITAL   (Japan)

Author keywords

germ cell tumor; minimal residual disease; MOZ CBP; therapy related AML

Indexed keywords

BLEOMYCIN; BUSULFAN; CD15 ANTIGEN; CD33 ANTIGEN; CD56 ANTIGEN; CISPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ETOPOSIDE; HLA ANTIGEN; HYBRID PROTEIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MICROSOMAL AMINOPEPTIDASE; MONOCYTIC LEUKEMIA ZINC FINGER PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOPEROXIDASE; NONSPECIFIC ESTERASE; TACROLIMUS; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD ANALYSIS; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME HIGH RESOLUTION BANDING ANALYSIS; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 8; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GERM CELL TUMOR; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; KARYOTYPE 46,XX; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MYELOBLAST; OVARIECTOMY; OVARY TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; THERAPY RELATED ACUTE MYELOID LEUKEMIA; TREATMENT RESPONSE;

ADOLESCENT; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 8; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM, RESIDUAL; NEOPLASMS, SECOND PRIMARY; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC;

EID: 84862889586     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318238818f     Document Type: Article

References (17)

1. Haferlach T, Kohlmann A, Klein HU, et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomor-phological, cytogenetic, molecular and prognostic features. Leukemia. 2009;23:934-943.
2. Gervais C, Murati A, Helias C, et al. Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogenetique hematologique. Leukemia. 2008;22:1567-1575.
3. Panagopoulos I, Isaksson M, Lindvall C, et al. RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13). Genes Chromosomes Cancer. 2000;28:415-424. (Pubitemid 30451794)
4. Panagopoulos I, Isaksson M, Lindvall C, et al. Genomic characterization of MOZ/CBP and CBP/MOZ chimeras in acute myeloid leukemia suggests the involvement of a damage-repair mechanism in the origin of the t(8;16)(p11;p13). Genes Chromosomes Cancer. 2003;36:90-98. (Pubitemid 36077385)
5. Schmidt HH, Strehl S, Thaler D, et al. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications. Leukemia. 2004;18:1115-1121. (Pubitemid 38786970)
6. Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia. 2006;20: 87-94.
7. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lympho-blastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206-3214.
8. Kern W, Haferlach C, Haferlach T, et al. Monitoring of minimal residual disease in acute myeloid leukemia. Cancer. 2008;112:4-16.
9. Liu HX, Zhu P, Zhang Y, et al. Real-time PCR array for simultaneous detection of 37 kinds of fusion genes in leukemia. Zhonghua Yi Xue Za Zhi. 2007;87:526-532. (Pubitemid 46647469)
10. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007-4013.
11. van der Velden VH, Panzer-Grumayer ER, Cazzaniga G, et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multicenter setting. Leukemia. 2007;21:706-713. (Pubitemid 46444554)
12. Kern W, Schoch C, Haferlach T, et al. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol. 2005;56:283-309. (Pubitemid 41565555)
13. Papadaki C, Dufour A, Seibl M, et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol. 2009;144:517-523.
14. Willasch AM, Gruhn B, Coliva T, et al. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia. 2009;23:1472-1479.
15. Stentoft J, Hokland P, Ostergaard M, et al. Minimal residual core binding factor AMLs by real time quantitative PCR\- initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res. 2006;30:389-395. (Pubitemid 43254960)
16. Rubinitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukemia: results of the AML02 multicenter trial. Lancet Oncol. 2010;11: 543-552.
17. Bader P, Kreyenberg H, Henze GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27:377-384.